Davita Inc. DVA
We take great care to ensure that the data presented and summarized in this overview for DAVITA INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DVA
View all-
Warren Buffett Berkshire Hathaway Inc | Omaha, Ne36.1MShares$5.11 Billion2.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.21MShares$738 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.94MShares$699 Million0.02% of portfolio
-
State Street Corp Boston, MA2.34MShares$332 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.59MShares$225 Million0.05% of portfolio
-
Morgan Stanley New York, NY1.46MShares$206 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.15MShares$163 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL1.03MShares$146 Million0.36% of portfolio
-
Dimensional Fund Advisors LP Austin, TX902KShares$128 Million0.03% of portfolio
-
Ubs Group Ag756KShares$107 Million0.02% of portfolio
Latest Institutional Activity in DVA
Top Purchases
Top Sells
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Insider Transactions at DVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 15
2025
|
Adam H Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+8.06%
|
-
|
|
Mar 15
2025
|
Joel Ackerman CFO and Treasuer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,424
-2.19%
|
$918,632
$143.45 P/Share
|
|
Mar 15
2025
|
Joel Ackerman CFO and Treasuer |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+3.89%
|
-
|
|
Mar 15
2025
|
David Paul Maughan Chief Operating Officer, DKC |
SELL
Payment of exercise price or tax liability
|
Direct |
9,333
-3.41%
|
$1,334,619
$143.45 P/Share
|
|
Mar 15
2025
|
David Paul Maughan Chief Operating Officer, DKC |
BUY
Grant, award, or other acquisition
|
Direct |
5,228
+3.62%
|
-
|
|
Mar 15
2025
|
Wendy Lee Schoppert Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
-
|
|
Mar 15
2025
|
Barbara J Desoer Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
-
|
|
Mar 15
2025
|
Kathleen Alyce Waters Chief Legal & Pub. Affairs Off |
SELL
Payment of exercise price or tax liability
|
Direct |
7,338
-1.79%
|
$1,049,334
$143.45 P/Share
|
|
Mar 15
2025
|
Kathleen Alyce Waters Chief Legal & Pub. Affairs Off |
BUY
Grant, award, or other acquisition
|
Direct |
3,346
+3.09%
|
-
|
|
Mar 15
2025
|
Phyllis R Yale Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+2.64%
|
-
|
|
Mar 15
2025
|
Pamela M Arway Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+1.36%
|
-
|
|
Mar 15
2025
|
Charles Berg Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+1.75%
|
-
|
|
Mar 15
2025
|
Jason M. Hollar Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+6.66%
|
-
|
|
Mar 15
2025
|
Christopher Michael Berry Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,834
+19.34%
|
-
|
|
Mar 15
2025
|
Gregory J. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+5.41%
|
-
|
|
Mar 15
2025
|
Dennis W Pullin Director |
BUY
Grant, award, or other acquisition
|
Direct |
349
+26.64%
|
-
|
|
Mar 15
2025
|
James O Hearty Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,319
-1.94%
|
$331,617
$143.45 P/Share
|
|
Mar 15
2025
|
James O Hearty Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,185
+3.72%
|
-
|
|
Mar 15
2025
|
Javier Rodriguez Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,822
+2.06%
|
-
|
|
Mar 12
2025
|
Kathleen Alyce Waters Chief Legal & Pub. Affairs Off |
BUY
Grant, award, or other acquisition
|
Direct |
10,718
+5.14%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 117K shares |
|---|---|
| Exercise of conversion of derivative security | 868K shares |
| Open market or private sale | 1.18M shares |
|---|---|
| Bona fide gift | 3.5K shares |
| Sale (or disposition) back to the issuer | 391K shares |
| Payment of exercise price or tax liability | 238K shares |